Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

One of biotech’s highest fliers, Sarepta Therapeutics, lost more than a third of its market value on Friday after executives said that one of its experimental gene-replacement therapies was linked to ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

Analysts are intrested in these 5 stocks: ( ($JPM) ), ( ($SBUX) ), ( ($HPE) ), ( ($SRPT) ) and ( ($ELV) ). Here is a breakdown of their recent ...